肿瘤浸润淋巴细胞、PD-L1、CD8与FOXP3整合构建三阴性乳腺癌预后模型
该研究纳入244例接受手术和化疗的I-III期三阴性乳腺癌患者,评估PD-L1、CD8和FOXP3在经典因素和TILs之外对预后模型的优化作用。结果显示PD-L1提供最大额外预后信息,新辅助化疗后未达pCR者残留病灶中CD8和PD-L1表达较基线显著升高。
要点
- TILs、PD-L1、CD8与FOXP3相互正相关(P<0.001),TILs为独立预后因素。
- 在经典因素和TILs基础上,PD-L1提供最大额外预后信息(LR χ2 4.60,P=0.032)。
- 新辅助化疗未达pCR者残留病灶中CD8和PD-L1表达较基线显著升高。
核心结论
- 在经典临床病理因素和TILs之外,其他免疫生物标志物可为早期三阴性乳腺癌提供额外预后信息。
- 新辅助化疗后残留病灶中PD-L1表达升高,支持在新辅助后阶段测试免疫检查点抑制剂。
研究设计与样本
- 研究纳入244例接受手术和化疗的I-III期三阴性乳腺癌患者,采集原发肿瘤样本。
- stromal TILs按指南在H&E切片上评估,PD-L1、CD8和FOXP3通过免疫组化及数字病理评估。
主要发现
- TILs、PD-L1、CD8和FOXP3彼此正相关(P<0.001)。
- TILs被确认为独立预后因素。
- 在包含经典因素和TILs(10%增量)的模型中,PD-L1的似然比χ2为4.60(P=0.032)。
- 在包含经典因素和TILs(>30% vs <30%)的模型中,PD-L1的似然比χ2为6.50(P=0.011)。
- 在接受新辅助化疗的患者亚组中,FOXP3在经典因素、TILs和pCR之外提供进一步预后信息(似然比χ2 5.01,P=0.025)。
临床怎么用
- 对早期三阴性乳腺癌,可在经典因素和TILs基础上整合PD-L1等免疫标志物以细化预后评估。
- 新辅助化疗后残留病灶中PD-L1表达升高,提示新辅助后阶段可考虑免疫检查点抑制剂相关研究或治疗决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Tumour infiltrating lymphocytes (TILs) are an established prognostic biomarker for triple-negative breast cancer (TNBC). We evaluated the role of programmed cell-death ligand-1 (PD-L1), CD8 and FOXP3 expression in refining a prognostic model for non-metastatic TNBC beyond classic factors and TILs. METHODS: Primary tumour samples from 244 early patients with TNBC, all treated with surgery and chemotherapy, were collected. Stromal TILs were evaluated on haematoxylin-eosin slides according to guidelines. PD-L1, CD8 and FOXP3 were assessed by immunohistochemistry and evaluated by digital pathology. RESULTS: TILs, PD-L1, CD8 and FOXP3 were positively correlated with each other (P < 0.001). TILs were confirmed as an independent prognostic factor. When PD-L1, CD8 and FOXP3 were added to multivariable models including classic factors (age, stage, histologic grade) and TILs, PD-L1 provided the largest amount of additional prognostic information: likelihood ratio χ2 4.60, P = 0.032 (in a model including classic factors and TILs 10% increments) and likelihood ratio χ2 6.50, P = 0.011 (in a model including classic factors and TILs >30% versus <30%). In the subset of patients treated with neoadjuvant chemotherapy, FOXP3 provided further prognostic information beyond classic factors, TILs and pathological complete response (pCR) (likelihood ratio χ2 5.01, P = 0.025). For patients who did not achieve a pCR, the expression of CD8 and PD-L1 was significantly increased from baseline to residual disease. CONCLUSIONS: Beyond clinicopathological factors and TILs, other immune biomarkers may add prognostic information for early TNBC. The increased PD-L1 expression on residual disease after neoadjuvant chemotherapy strengthens the rationale of testing immune checkpoint inhibitors in the post-neoadjuvant setting.
引用
- Dieci MV, Tsvetkova V, Griguolo G, et al. Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I-III patients treated with standard therapy. Eur J Cancer. 2020. PMID: 32622323. doi:10.1016/j.ejca.2020.05.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。